Click Here for 5% Off Your First Aladdin Purchase!

(2R)-2-[5-[6-amino-5-[(1R)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol , CAS No.R609456, Inhibitor of ALK receptor tyrosine kinase;Inhibitor of c-ros oncogene 1; receptor tyrosine kinase;Inhibitor of FER tyrosine kinase;Inhibitor of FES proto-oncogene; tyrosine kinase;Inhibitor of leukocyte receptor tyrosine kinase;Inhibitor of mitogen-activa

  • Moligand™
Item Number
R609456
Grouped product items
SKUSizeAvailabilityPrice Qty
R609456-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$710.90
R609456-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,300.90

Basic Description

Synonyms1549629-82-4|PF-06439015|CHEMBL3128069|76PND635L1|compound 8e [PMID: 24432909]|(2R)-2-(5-(6-Amino-5-((1R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)-3-pyridinyl)-4-methyl-2-thiazolyl)-1,2-propanediol|1,2-Propanediol, 2-(5-(6-amino-5-((1R)-1-(5-fl
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of ALK receptor tyrosine kinase;Inhibitor of c-ros oncogene 1; receptor tyrosine kinase;Inhibitor of FER tyrosine kinase;Inhibitor of FES proto-oncogene; tyrosine kinase;Inhibitor of leukocyte receptor tyrosine kinase;Inhibitor of mitogen-activa

Associated Targets

PTK2 Tclin Focal adhesion kinase 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ROS1 Tclin Proto-oncogene tyrosine-protein kinase ROS 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FER Tclin Tyrosine-protein kinase Fer 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FES Tclin Tyrosine-protein kinase Fes/Fps 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTK2B Tclin Protein-tyrosine kinase 2-beta 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

LTK Tclin Leukocyte tyrosine kinase receptor 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TNK2 Tclin Activated CDC42 kinase 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ALK Tclin ALK tyrosine kinase receptor 18 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NTRK2 Tclin BDNF/NT-3 growth factors receptor 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NTRK1 Tclin High affinity nerve growth factor receptor 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NTRK3 Tclin NT-3 growth factor receptor 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

JAK2 Tclin Tyrosine-protein kinase JAK2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAP3K9 Tchem Mitogen-activated protein kinase kinase kinase 9 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (2R)-2-[5-[6-amino-5-[(1R)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol
INCHI InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
InChi Key DIXMBHMNEHPFCX-MCMMXHMISA-N
Canonical SMILES OC[C@](c1nc(c(s1)c1cnc(c(c1)O[C@@H](c1cc(F)ccc1n1nccn1)C)N)C)(O)C
Isomeric SMILES CC1=C(SC(=N1)[C@@](C)(CO)O)C2=CC(=C(N=C2)N)O[C@H](C)C3=C(C=CC(=C3)F)N4N=CC=N4
PubChem CID 72710568

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook AS, Cui JJ, Dack KN et al..  (2014)  Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib..  J Med Chem,  57  (4): (1170-87).  [PMID:24432909]

Solution Calculators